Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.31 USD
+0.03 (0.29%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $10.30 -0.01 (-0.10%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Amicus Therapeutics, Inc. [FOLD]
Reports for Purchase
Showing records 101 - 120 ( 176 total )
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Model Update Incorporates Galafold FY20 Outlook
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Galafold Chugging Along With a 4Q19 Beat, FY20 Guidance Next Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Post Recent C-Suite/Investor Meetings
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Recap; Galafold, AT-GAA, and Beyond; Target Increased to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Post Investor Day: Lots to Like Over a 12+ Month Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Maturing AT-GAA Pompe Data Reinforce the Dream
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1H19 Recap: Execution Across the Burgeoning Pipeline Is the Theme
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CLN6 Gene Therapy Changes the Course of Another Scourge
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Previewing 2Q19; Expectations Around Galafold and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Democratization of AAV Availability Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D